Akebia Therapeutics, Inc. (AKBA)

Market Cap	390.54M
Revenue (ttm)	169.88M
Net Income (ttm)	-45.99M
Shares Out	218.18M
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,147,632
Open	1.800
Previous Close	1.820
Day's Range	1.780 - 1.820
52-Week Range	0.800 - 2.480
Beta	0.73
Analysts	Strong Buy
Price Target	5.75 (+221.23%)
Earnings Date	Nov 7, 2024

About AKBA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult pa...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Mar 20, 2014
• Employees: 167
• Stock Exchange: NASDAQ
• Ticker Symbol: AKBA
• Website: https://www.akebia.com

Financial Performance

In 2023, Akebia Therapeutics's revenue was $194.62 million, a decrease of -33.46% compared to the previous year's $292.48 million. Losses were -$51.93 million, -44.89% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for AKBA stock is "Strong Buy." The 12-month stock price forecast is $5.75, which is an increase of 221.23% from the latest price.

Price Target

$5.75

(221.23% upside)

Analyst Consensus: Strong Buy